Piramal Pharma marked a key milestone with the groundbreaking of its Lexington, Kentucky facility expansion. The $90 million investment is set to more than double the site’s manufacturing capacity—from 104 to over 240 product batches annually by late 2027—strengthening the company's position in the growing sterile injectables and antibody-drug conjugates (ADC) markets.
The expansion comes at a pivotal moment for sterile injectables, a market projected to exceed $20 billion by 2028. This surge is fueled by increased clinical use, regulatory approvals, and innovations in delivery systems that enhance both safety and efficacy. ADC therapies, too, are gaining momentum as promising precision immunotherapies in oncology, underscoring the need for expanded production capabilities.
“Our research confirms the rising need for advanced biologics,” said Nandini Piramal, Chairperson, Piramal Pharma. “This investment empowers us to scale our offerings and better serve patients worldwide while reinforcing our commitment to patient, consumer, and customer centricity.”
Peter DeYoung, CEO of Piramal Global Pharma, added, “ADCs are becoming a cornerstone in targeted cancer therapies. Through investments in both our Lexington and Riverview facilities, we are boosting our integrated ADCelerate™ platform to meet this growing demand.”
Beyond manufacturing, the Lexington expansion is also a commitment to the local economy. The project will create 40 new full-time jobs and strengthen Piramal’s partnership with regional stakeholders. The company emphasized its dedication to U.S.-based production and supply chain resilience, aligning with national trends toward onshore manufacturing.
Lexington Mayor Linda Gorton lauded the development, stating, “Piramal’s expansion reinforces Lexington’s reputation as a hub for pharmaceutical innovation. With assets like the University of Kentucky College of Pharmacy, we’re becoming a center of excellence in life sciences.”
Industry partners shared the enthusiasm. Jim Stephanou, CEO of IPS-Integrated Project Services, highlighted their long-standing collaboration with Piramal, while Bob Quick, President and CEO of Commerce Lexington, called the project a win for the region’s biotech sector.
This expansion marks a strategic step for Piramal Pharma Solutions as it strengthens its global manufacturing footprint, supports innovation in biologics, and remains focused on improving patient outcomes through scalable, high-quality therapies.